aod9604 human trials Onset Half Life AOD9604 – Montreal Peptides Canada

In men, it drives characteristics such as deeper voice, increased muscle mass, and libido

A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007

Its primary function is to transfer a methyl group to nicotinamide, a form of vitamin B3

Although dietary fiber has been associated with microbiome changes 75 , this is unlikely to account for the microbiome changes observed herein since fiber content was the same across diets

Some common side effects may include: Irritation at the injection site Fatigue Nausea Storage Store at controlled room temperature

The first gap is species